Where can I buy generic adagrasib?

Adagrasib is a targeted drug used to treat KRAS G12C mutated non-small cell lung cancer. It has not yet been approved for marketing in my country. Therefore, if domestic patients need to use the drug, they can only purchase it through overseas channels. There are many versions of this drug internationally, including original drugs and generic drugs. Patients need to be extra cautious when choosing drug purchase channels to ensure the safety and legality of the drugs they purchase.

Currently, the original adagrasibu drug on the market in the United States is very expensive, with the price of each box being as high as hundreds of thousands of yuan. For most ordinary patient families, such costs are undoubtedly a heavy financial burden. Although the original drug has proven efficacy, its high price limits its global accessibility. Therefore, many patients have turned their attention to relatively cheaper versions of generic drugs.

Among the many sources of generic drugs, drugs from Laos have attracted attention due to their high cost performance. At present, several local pharmaceutical companies in Laos have launched generic versions of adagrasib, with each box selling for about more than 3,000 yuan. This generic drug is basically the same as the original drug in terms of ingredients, and has shown good results in the treatment of KRAS G12C mutation-related cancers, making it one of the viable options for patients with limited economic conditions. Patients can usually obtain these drugs through formal overseas drug purchasing platforms or medical service intermediaries.

In general, since adagrasib has not yet been marketed in China, patients should purchase it through formal and legal overseas channels to avoid delays in treatment due to mistaken purchase of counterfeit or inferior drugs. It is recommended that patients undergo KRAS G12C mutation testing before taking medications and use medications rationally under the guidance of professional oncologists. At the same time, we should continue to pay attention to the progress of the drug's launch in China. In the future, it is expected that treatment will be safer and more convenient through the formal medical system.

References：https://www.krazati.com/